Decreased Serum Kruppel-Like Factor 7 Level is Positively Associated with Low-Density Lipoprotein Cholesterol Level in Women with Polycystic Ovary Syndrome

2019 ◽  
Vol 65 (04/2019) ◽  
Author(s):  
Gangxi Pan ◽  
Bohui Ouyang ◽  
Lin Sun ◽  
Sufeng Li ◽  
Jianlin Chen ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Cholesterol Level ◽  
Polycystic Ovary ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Ovary Syndrome

scholarly journals Prediction of Gut Microbial Community Structure and Function in Polycystic Ovary Syndrome With High Low-Density Lipoprotein Cholesterol

2021 ◽  
Vol 11 ◽  
Author(s):  
Xuping Zhu ◽  
Yanyu Li ◽  
Yanmin Jiang ◽  
Jisheng Zhang ◽  
Ru Duan ◽  
...  
Keyword(s):  
Microbial Community ◽  
Polycystic Ovary Syndrome ◽  
Gut Microbiota ◽  
Polycystic Ovary ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Ovary Syndrome ◽  
Gut Microbial Community

Gut microbiota has been proved to be involved in the occurrence and development of many diseases, such as type 2 diabetes, obesity, coronary heart disease, etcetera. It provides a new idea for the pathogenesis of polycystic ovary syndrome (PCOS). Our study showed that the gut microbial community of PCOS with high low-density lipoprotein cholesterol (LDLC) has a noticeable imbalance. Gut microbiota of PCOS patients was significantly changed compared with CON, and these changes were closely related to LDLC. Gut microbiota may affect the metabolic level of PCOS patients through multiple metabolic pathways, and lipid metabolism disorder may further aggravate the imbalance of gut microbiota. Actinomycetaceae, Enterobacteriaceae and Streptococcaceae had high accuracy in the diagnosis of PCOS and the differentiation of subgroups, suggesting that they may play an important role in the diagnosis and treatment of PCOS in the future. Also, the model we built showed good specificity and sensitivity for distinguishing PCOS from CON (including L_CON and L_PCOS, H_CON and H_PCOS). In conclusion, this is the first report on the gut microbiota of PCOS with high LDLC, suggesting that in the drug development or treatment of PCOS patients, the difference of gut microbiota in PCOS patients with different LDLC levels should be fully considered.

Sign in / Sign up

Export Citation Format

Share Document